Wednesday, June 10, 2026

Patent intelligence · PT

PT 2121138

THERAPEUTICAL USES OF ESLICARBAZEPINE

granted A61K 31/ 55 A IA61K 45/ 06 A IA61K/3155A61K/4506
Status granted
Years to expiry 11
Applicant portfolio 21
Patent details — PT 2121138
Jurisdiction
PT
Status
granted
Grant date
Dec 20, 2016
Expiration
Dec 15, 2036
CPC classes
A61K 31/ 55 A I, A61K 45/ 06 A I, A61K/3155, A61K/4506
View on Google Patents ↗

Quick answer

PT 2121138 (THERAPEUTICAL USES OF ESLICARBAZEPINE) is held by BIAL-PORTELA & Cª S A [PT]. Status: granted. Granted Dec 20, 2016. Expires Dec 15, 2036 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 31/ 55 A I, A61K 45/ 06 A I, A61K/3155, A61K/4506, A61P 25/ 04 A I, A61P 25/ 08 A I

More from BIAL-PORTELA & Cª S A [PT]

Related pharmaceutical patents in our USPTO index.

  1. WO 2022081033

    OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

    BIAL PORTELA & Cª S A [PT] · Expires Apr 16, 2042

    granted
  2. WO 2022025781

    DISPERSION SOLIDE D'OPICAPONE

    BIAL PORTELA & Cª S A [PT] · Expires Jan 29, 2042

    granted
  3. WO 2021182981

    OPICAPONE MICRONISÉE

    BIAL PORTELA & Cª S A [PT] · Expires Sep 11, 2041

    granted
  4. WO 2020246903

    INHIBITEURS DE DOPAMINE-B-HYDROXYLASE

    BIAL PORTELA & Cª S A [PT] · Expires Dec 5, 2040

    granted
  5. AU 2018379646

    Dopamine-B-hydroxylase inhibitors

    BIAL PORTELA & Cª S A [PT] · Expires Jun 6, 2040

    granted
  6. BR PI0923819

    compostos farmacêuticos

    BIAL PORTELA & Cª S A [PT] · Expires Nov 14, 2039

    granted
  7. EP 3515433

    DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN

    BIAL PORTELA & Cª S A [PT] · Expires Jul 26, 2039

    granted
  8. US 2019008774

    PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME

    BIAL PORTELA & Cª S A [PT] · Expires Jan 5, 2039

    granted

Frequently asked questions

What is US patent 2121138?

PT 2121138 (THERAPEUTICAL USES OF ESLICARBAZEPINE) is held by BIAL-PORTELA & Cª S A [PT]. Status: granted. Granted Dec 20, 2016. Expires Dec 15, 2036 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns PT 2121138?

BIAL-PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.

When does PT 2121138 expire?

Our index shows an expiration date of Dec 15, 2036 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.